SB17170 Phase 1 Clinical Trial in Solid Tumors

Status:
Not yet recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Phase 1 Open-label, multicenter, dose escalation, dose expansion study

Phase 1

SPARK Biopharma